CN103743906B - 用于测定造血干细胞移植后患者骨髓微环境的试剂盒、系统及方法 - Google Patents
用于测定造血干细胞移植后患者骨髓微环境的试剂盒、系统及方法 Download PDFInfo
- Publication number
- CN103743906B CN103743906B CN201310313512.9A CN201310313512A CN103743906B CN 103743906 B CN103743906 B CN 103743906B CN 201310313512 A CN201310313512 A CN 201310313512A CN 103743906 B CN103743906 B CN 103743906B
- Authority
- CN
- China
- Prior art keywords
- bone marrow
- hematopoietic stem
- stem cell
- patient
- cell transplantation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title abstract description 29
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 67
- 210000004027 cell Anatomy 0.000 claims abstract description 58
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 238000003860 storage Methods 0.000 claims abstract description 12
- 238000010586 diagram Methods 0.000 claims abstract description 11
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 52
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 52
- 239000007943 implant Substances 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 33
- 238000004458 analytical method Methods 0.000 claims description 14
- 238000011156 evaluation Methods 0.000 claims description 14
- 238000002513 implantation Methods 0.000 claims description 13
- 238000004891 communication Methods 0.000 claims description 12
- 238000004043 dyeing Methods 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 7
- 238000013459 approach Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 238000007405 data analysis Methods 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 abstract description 5
- 208000014951 hematologic disease Diseases 0.000 abstract description 5
- 208000018706 hematopoietic system disease Diseases 0.000 abstract description 5
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 5
- 238000002054 transplantation Methods 0.000 abstract description 3
- 208000023661 Haematological disease Diseases 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 15
- 230000036541 health Effects 0.000 description 15
- 208000024908 graft versus host disease Diseases 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 7
- 238000013016 damping Methods 0.000 description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002969 morbid Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 210000004786 perivascular cell Anatomy 0.000 description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000001215 fluorescent labelling Methods 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012113 quantitative test Methods 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 238000004451 qualitative analysis Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 201000001383 blood group incompatibility Diseases 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
患者特征 | 植入不良组(n=19) | 植入良好组(n=38) | P-Valueb |
骨髓微环境评估时间 (移植后天数) | 90(58-264) | 90(30-270) | 0.61 |
骨髓细胞增生程度 (%)(范围) | 10(5-15) | 45(30-50) | <0.0001 |
骨髓微环境成分 | |||
CD45-CD34+CD146+ (%)(范围) | 0.008(0.001-0.03) | 0.10(0.02-0.23) | <0.0001 |
CD45-CD34+CD146+ (每个血管)(范围) | 1(0-3) | 4(2-6) | <0.0001 |
外周血细胞计数 | |||
中位白细胞计数 (×109/L) (范围) | 1.73(0.32-5.34) | 5(3.10-7.60) | <0.0001 |
中位中性粒细胞计数 (×109/L) (范围) | 1.10(0.16-6.50) | 3.65(1.55-6.38) | <0.0001 |
中位血红蛋白水平 (g/L) (范围) | 76(56-103) | 120(78-151) | <0.0001 |
中位 血小板计数 (×109/L) (范围) | 17(9-142) | 119(61-243) | <0.0001 |
移植时年龄 (岁, 中位值, 范围) | 27(16-57) | 35.5(16-55) | 0.48 |
性别 (男/女) | 9/10 | 23/15 | 0.40 |
疾病诊断 | |||
急性髓细胞白血病 | 4 | 9 | 1.00 |
急性淋巴细胞白血病 | 9 | 17 | 1.00 |
慢性粒细胞白血病 | 2 | 4 | 1.00 |
骨髓增生异常综合征 | 4 | 8 | 1.00 |
移植时疾病状态 | 0.11 | ||
标危 | 16 | 25 | |
高危 | 3 | 13 | |
确诊到移植的中位时间 (月, 范围) | 12(4-20) | 10(2-30) | 0.32 |
干细胞来源 | 1.00 | ||
骨髓和外周血 | 17 | 34 | |
外周血 | 2 | 4 | |
移植的单个核细胞数(×108/ 公斤,中位值, 范围) | 8.06(5.34-15.34) | 7.59(3.50-10.08) | 0.12 |
移植的CD34+细胞数(×106/公斤,中位值, 范围) | 2.38(1.23-3.96) | 2.26(0.90-3.94) | 0.80 |
供者HLA匹配 | |||
HLA-全合同胞供者 | 2 | 10 | 0.30 |
HLA-部分相合同胞供者 | 15 | 22 | 0.15 |
HLA-全合无关供者 | 2 | 4 | 1.00 |
供受者性别匹配 | |||
女供男 | 5 | 6 | 0.48 |
女供女 | 1 | 2 | 1.00 |
男供女 | 9 | 11 | 0.15 |
男供男 | 4 | 15 | 0.24 |
供受者ABO 血型不合 | |||
无 | 13 | 27 | 1.00 |
小不合 | 2 | 2 | 0.59 |
危险因素 | 单因素P-Value |
基本特征 | |
性别,女 vs. 男 | 0.27 |
年龄 | 0.81 |
疾病特点 | |
诊断,骨髓增生异常综合症 vs. 白血病 | 0.04* |
状态,高危vs. 低危 | |
移植前化疗 | |
化疗疗程 | 0.70 |
移植特征 | |
供受者匹配,同胞全合 vs. 同胞半相合 vs. 无关全合 | 0.15 |
HLA不合位点,≥ 2位点 vs. 0-1 位点 | 0.10 |
性别不合,女男 vs.女女 vs. 男女vs. 男男 | 0.12 |
ABO血型不合,无 vs.小不合 vs. 大不合 | 0.21 |
干细胞来源,骨髓+外周血 vs. 外周血 | 1.00 |
预处理,改良 BU/CY+ATG vs. 其他 | 0.15 |
移植的单个核细胞数,≥7.37×108/ kg vs. < 7.37×108/ kg | 0.45 |
移植的 CD34+细胞数,≥2.3×106/ kg vs. < 2.3×106/ kg | 0.42 |
移植相关并发症 | |
移植物抗宿主病史,有vs. 无 | 0.03* |
巨细胞病毒感染史,有vs. 无 | 0.11 |
骨髓微环境成分 | |
移植后评估时间 | 0.33 |
aCD146+血管周围细胞,<0.025% vs. ≥0.025% | <0.0001* |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310313512.9A CN103743906B (zh) | 2013-07-24 | 2013-07-24 | 用于测定造血干细胞移植后患者骨髓微环境的试剂盒、系统及方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310313512.9A CN103743906B (zh) | 2013-07-24 | 2013-07-24 | 用于测定造血干细胞移植后患者骨髓微环境的试剂盒、系统及方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103743906A CN103743906A (zh) | 2014-04-23 |
CN103743906B true CN103743906B (zh) | 2015-05-20 |
Family
ID=50500941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310313512.9A Active CN103743906B (zh) | 2013-07-24 | 2013-07-24 | 用于测定造血干细胞移植后患者骨髓微环境的试剂盒、系统及方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103743906B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109633143B (zh) * | 2018-12-28 | 2022-05-17 | 广东省心血管病研究所 | 一种测定造血干细胞移植后患者骨髓微循环环境检测的系统和方法 |
CN109727671B (zh) * | 2018-12-28 | 2021-07-09 | 广东省心血管病研究所 | 一种鉴定造血干细胞移植术效果的信息分析系统及方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221359B1 (en) * | 1991-07-26 | 2001-04-24 | Toray Industries, Inc. | Hemopoietic stem cell multiplier |
CN1407088A (zh) * | 2001-09-06 | 2003-04-02 | 周胜利 | 从胎盘组织中提取造血干细胞用于建立造血干细胞库的新方法 |
CN1410532A (zh) * | 2002-03-21 | 2003-04-16 | 上海凡华生物技术有限公司 | 一种人/山羊肝嵌合模型的建立及其鉴定方法 |
CN101238218A (zh) * | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
CN101309653A (zh) * | 2005-11-15 | 2008-11-19 | 奥巴斯尼茨医学公司 | 夺取祖内皮细胞的药物洗脱可移植的医疗设备 |
CN101437937A (zh) * | 2006-03-07 | 2009-05-20 | 哈玛赛特公司 | 从脂肪组织提取内皮细胞的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002098695A (ja) * | 2000-09-22 | 2002-04-05 | Toagosei Co Ltd | 造血幹細胞移植後の肝中心静脈閉塞症の検査方法および治療薬 |
-
2013
- 2013-07-24 CN CN201310313512.9A patent/CN103743906B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221359B1 (en) * | 1991-07-26 | 2001-04-24 | Toray Industries, Inc. | Hemopoietic stem cell multiplier |
CN1407088A (zh) * | 2001-09-06 | 2003-04-02 | 周胜利 | 从胎盘组织中提取造血干细胞用于建立造血干细胞库的新方法 |
CN1410532A (zh) * | 2002-03-21 | 2003-04-16 | 上海凡华生物技术有限公司 | 一种人/山羊肝嵌合模型的建立及其鉴定方法 |
CN101238218A (zh) * | 2005-05-20 | 2008-08-06 | 维克西斯公司 | 初级细胞的转导 |
CN101309653A (zh) * | 2005-11-15 | 2008-11-19 | 奥巴斯尼茨医学公司 | 夺取祖内皮细胞的药物洗脱可移植的医疗设备 |
CN101437937A (zh) * | 2006-03-07 | 2009-05-20 | 哈玛赛特公司 | 从脂肪组织提取内皮细胞的方法 |
Non-Patent Citations (2)
Title |
---|
外周血肝细胞移植前后骨髓微环境细胞粘附分子的临床研究;陈幸华等;《重庆医学》;20031031;第32卷(第10期);1283-1285 * |
自体外周血CD34+造血干细胞移植治疗多发性骨髓瘤;杨树军等;《中国肿瘤》;20011231;第10卷(第8期);492-493 * |
Also Published As
Publication number | Publication date |
---|---|
CN103743906A (zh) | 2014-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6352588B2 (ja) | 希少ではない細胞を用いて希少細胞を検出する方法 | |
Balic et al. | Circulating tumor cells: from bench to bedside | |
TWI539158B (zh) | 使用血液中之循環黑色素瘤細胞預測黑色素瘤病患之臨床結果的方法。 | |
Kolostova et al. | Isolation, primary culture, morphological and molecular characterization of circulating tumor cells in gynecological cancers | |
JP5479355B2 (ja) | 血液中の循環黒色腫細胞の自動計数及び特徴付け | |
Peceliunas et al. | Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma | |
CN105223361A (zh) | 一种检测急性t淋巴细胞白血病幼稚t细胞的试剂盒、应用及方法 | |
Wallace et al. | Converting fluid‐based cytologic specimens to histologic specimens for immunohistochemistry | |
CN103743906B (zh) | 用于测定造血干细胞移植后患者骨髓微环境的试剂盒、系统及方法 | |
Nassar et al. | A multisite performance study comparing the reading of immunohistochemical slides on a computer monitor with conventional manual microscopy for estrogen and progesterone receptor analysis | |
Wang et al. | Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma | |
CN103743907B (zh) | 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法 | |
CN102435734A (zh) | 卵巢癌原发化疗敏感性测评试剂盒及其应用 | |
Rödiger et al. | Quantification of DNA double-strand breaks in peripheral blood mononuclear cells from healthy donors exposed to bendamustine by an automated γH2AX assay—an exploratory study | |
Brodard et al. | Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia | |
Su et al. | Multiplex immunohistochemistry and high-throughput image analysis for evaluation of spatial tumor immune cell markers in human breast cancer | |
EP2972377A1 (en) | Systems and methods employing human stem cell markers for detection, diagnosis and treatment of circulating tumor cells | |
CN113125751B (zh) | 外周血pd-1/pd-l1预测乳腺癌肿瘤组织中pd-l1水平的方法 | |
CN113257370B (zh) | 基于临床病理基本信息和vista检测的pnet复发风险预测模型 | |
CN103608681A (zh) | 用于检测肿瘤细胞的类固醇受体测定 | |
US20110136129A1 (en) | Assessing atypical hyperplasia patients for the risk of developing breast cancer | |
Halimi et al. | Association of Ki67 Antigen With Mitotic Count, Tumor Size, and Necrosis in Neuroendocrine Tumors of Lung. | |
Sheen-Chen et al. | Lack of prognostic value of insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray | |
Wu et al. | Polarized HLA Class I Expression on Renal Tubules Hinders the Detection of Donor-Specific Urinary Extracellular Vesicles | |
Weng et al. | Comparison of PD-L1 detection methods, platforms and reagents in bladder cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181228 Address after: 201318 Lane 21, 908 Ziping Road, Pudong New Area, Shanghai Patentee after: SHANGHAI TISSUEBANK MEDICAL LABORATORY Co.,Ltd. Address before: 100044 No. 11 South Main Street, Xicheng District, Beijing, Xizhimen Patentee before: PEKING UNIVERSITY PEOPLE'S Hospital |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Kit, system, and method for measuring the bone marrow microenvironment of patients after hematopoietic stem cell transplantation Effective date of registration: 20230719 Granted publication date: 20150520 Pledgee: Industrial Bank Co.,Ltd. Shanghai Nanhui Branch Pledgor: SHANGHAI TISSUEBANK MEDICAL LABORATORY Co.,Ltd.|SHENZHEN TISSUEBANK PRECISION MEDICINE CO.,LTD.|SHANGHAI TISSUEBANK BIOTECHNOLOGY Co.,Ltd.|Shanghai dishuobeiken Gene Technology Co.,Ltd.|SHANGHAI TISSUEBANK BIOTECHNOLOGY CO.,LTD. Registration number: Y2023310000384 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20150520 Pledgee: Industrial Bank Co.,Ltd. Shanghai Nanhui Branch Pledgor: SHANGHAI TISSUEBANK MEDICAL LABORATORY Co.,Ltd.|SHENZHEN TISSUEBANK PRECISION MEDICINE CO.,LTD.|SHANGHAI TISSUEBANK BIOTECHNOLOGY Co.,Ltd.|Shanghai dishuobeiken Gene Technology Co.,Ltd.|SHANGHAI TISSUEBANK BIOTECHNOLOGY CO.,LTD. Registration number: Y2023310000384 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Kit, system, and method for measuring the bone marrow microenvironment of patients after hematopoietic stem cell transplantation Granted publication date: 20150520 Pledgee: Industrial Bank Co.,Ltd. Shanghai Nanhui Branch Pledgor: SHANGHAI TISSUEBANK MEDICAL LABORATORY Co.,Ltd.|SHENZHEN TISSUEBANK PRECISION MEDICINE CO.,LTD.|SHANGHAI TISSUEBANK BIOTECHNOLOGY Co.,Ltd.|Shanghai dishuobeiken Gene Technology Co.,Ltd.|SHANGHAI TISSUEBANK BIOTECHNOLOGY CO.,LTD. Registration number: Y2024310000533 |